Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs Ionis Pharmaceuticals, Inc. Trends and Insights

Biotech SG&A Expenses: Corcept vs. Ionis

__timestampCorcept Therapeutics IncorporatedIonis Pharmaceuticals, Inc.
Wednesday, January 1, 20143491600020140000
Thursday, January 1, 20153694900037173000
Friday, January 1, 20164524000048616000
Sunday, January 1, 201762416000108488000
Monday, January 1, 201881289000244622000
Tuesday, January 1, 2019100359000287000000
Wednesday, January 1, 2020105326000354000000
Friday, January 1, 2021122356000186000000
Saturday, January 1, 2022152848000151000000
Sunday, January 1, 2023184259000232600000
Monday, January 1, 2024267474000
Loading chart...

In pursuit of knowledge

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Corcept Therapeutics Incorporated and Ionis Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Corcept's SG&A expenses grew by over 400%, starting at approximately $35 million and reaching nearly $184 million. Meanwhile, Ionis Pharmaceuticals saw a more dramatic increase, with expenses rising from $20 million to $233 million, marking an impressive 1,065% growth.

Key Insights

  • 2017 Surge: Ionis Pharmaceuticals experienced a significant spike in 2017, with expenses more than doubling from the previous year.
  • Recent Trends: By 2023, both companies showed a convergence in their SG&A expenses, indicating potential strategic shifts.

Understanding these trends provides valuable insights into the financial strategies and operational efficiencies of these biotech giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025